Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics (KYTX) to $27 from $24 and keeps an Overweight rating on the shares. The firm likes the risk/reward on KYV-101’s pivotal stiff person syndrome trial read out in the first half of 2026 and believes the Street underappreciates how de-risked the trial is.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Announces Board Member Resignation
- Kyverna Therapeutics: Promising Potential in MS and MG with Strong Financials and Conservative Valuation
- Kyverna Therapeutics’ KYV-101: Promising Efficacy and Safety in Multiple Sclerosis and Beyond
- Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101
- Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM